Chordate has only one class of shares and all shares have equal rights to dividend and surplus upon liquidation and one vote at the general meeting. Shareholders in the company have preferential rights when shares are issued, in proportion to existing holdings.
Chordate’s shares have been issued in accordance with Swedish law and are denominated in SEK. The company’s shares are registered with Euroclear in electronic form and Euroclear also keeps the company’s share book.
The company’s shares have been traded on Nasdaq First North Growth Market since February 15, 2022.
Stock symbol: CMH
Nasdaq First North Growth Market is an alternative marketplace run by the various stock exchanges included in NASDAQ. It has the same legal status as a regulated exchange. Companies on Nasdaq First North Growth Market are regulated by Nasdaq First North Growth Market’s rules and not by the legal requirements that are demanded for trading on a regulated exchange. An investment in a company that is traded on Nasdaq First North Growth Market carries more risk than an investment in a company listed on a regulated exchange. All companies, whose stock is listed for trading on Nasdaq First North Growth Market, have a Certified Advisor who assures that all regulations are observed. NASDAQ Stockholm approves applications to be included in trading on Nasdaq First North Growth Market.
Västra Hamnen Corporate Finance AB
+46 40 200 250
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.